



AMERICAN ACADEMY™
OF OPHTHALMOLOGY

7

Orbit, Eyelids, and Lacrimal System

Last major revision 2015–2016

2017–2018
BCSC
Basic and Clinical
Science Course™

Protecting Sight. Empowering Lives.™



Published after collaborative
review with the European Board
of Ophthalmology subcommittee

The American Academy of Ophthalmology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Academy of Ophthalmology designates this enduring material for a maximum of 10 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CME expiration date: June 1, 2018. AMA PRA Category 1 Credits™ may be claimed only once between June 1, 2015, and the expiration date.

BCSC® volumes are designed to increase the physician's ophthalmic knowledge through study and review. Users of this activity are encouraged to read the text and then answer the study questions provided at the back of the book.

To claim AMA PRA Category 1 Credits™ upon completion of this activity, learners must demonstrate appropriate knowledge and participation in the activity by taking the posttest for Section 7 and achieving a score of 80% or higher. For further details, please see the instructions for requesting CME credit at the back of the book.

The Academy provides this material for educational purposes only. It is not intended to represent the only or best method or procedure in every case, nor to replace a physician's own judgment or give specific advice for case management. Including all indications, contraindications, side effects, and alternative agents for each drug or treatment is beyond the scope of this material. All information and recommendations should be verified, prior to use, with current information included in the manufacturers' package inserts or other independent sources, and considered in light of the patient's condition and history. Reference to certain drugs, instruments, and other products in this course is made for illustrative purposes only and is not intended to constitute an endorsement of such. Some material may include information on applications that are not considered community standard, that reflect indications not included in approved FDA labeling, or that are approved for use only in restricted research settings. **The FDA has stated that it is the responsibility of the physician to determine the FDA status of each drug or device he or she wishes to use, and to use them with appropriate, informed patient consent in compliance with applicable law.** The Academy specifically disclaims any and all liability for injury or other damages of any kind, from negligence or otherwise, for any and all claims that may arise from the use of any recommendations or other information contained herein.

AAO, AAOE, American Academy of Ophthalmology, Basic and Clinical Science Course, BCSC, EyeCare America, EyeNet, EyeSmart, EyeWiki, Focal Points, IRIS, ISRS, OKAP, ONE, Ophthalmic Technology Assessments, *Ophthalmology*, Preferred Practice Pattern, ProVision, SmartSight, The Ophthalmic News & Education Network, and the AAO logo (shown on cover) and tagline (Protecting Sight. Empowering Lives.) are, among other marks, the registered trademarks and trademarks of the American Academy of Ophthalmology.

Cover image: From BCSC Section 5, *Neuro-Ophthalmology*. Fundus photograph showing an arteriovenous malformation (racemose angioma) of the retina in a patient with Wyburn-Mason syndrome. (Courtesy of Mark J. Greenwald, MD.)

Copyright © 2017 American Academy of Ophthalmology. All rights reserved.
No part of this publication may be reproduced without written permission.

Printed in the United States of America.

Basic and Clinical Science Course

Louis B. Cantor, MD, Indianapolis, Indiana, *Senior Secretary for Clinical Education*

Christopher J. Rapuano, MD, Philadelphia, Pennsylvania, *Secretary for Lifelong Learning and Assessment*

George A. Cioffi, MD, New York, New York, *BCSC Course Chair*

Section 7

Faculty

Jill Annette Foster, MD, *Chair*, Columbus, Ohio

Keith D. Carter, MD, Iowa City, Iowa

Vikram D. Durairaj, MD, Austin, Texas

Marsha C. Kavanagh, MD, Portsmouth, New Hampshire

Bobby S. Korn, MD, PhD, La Jolla, California

Christine C. Nelson, MD, Ann Arbor, Michigan

Morris E. Hartstein, MD, *Consultant*, Raanana, Israel

The Academy wishes to acknowledge the American Society of Ophthalmic Plastic and Reconstructive Surgery (ASOPRS) for recommending faculty members to the BCSC Section 7 committee.

The Academy also wishes to acknowledge the following committees for review of this edition:

Committee on Aging: Paul N. Rosenberg, MD, Webster, New York

Vision Rehabilitation Committee: Richard A. Harper, MD, Little Rock, Arkansas

Practicing Ophthalmologists Advisory Committee for Education: Robert G. Fante, MD, *Primary Reviewer*, Denver, Colorado; Edward K. Isbey III, MD, *Chair*, Asheville, North Carolina; Alice Bashinsky, MD, Asheville, North Carolina; David J. Browning, MD, PhD, Charlotte, North Carolina; Bradley Fouraker, MD, Tampa, Florida; Dasa Gangadhar, MD, Wichita, Kansas; Steven J. Grosser, MD, Golden Valley, Minnesota; James A. Savage, MD, Memphis, Tennessee



European Board of Ophthalmology: Peter Raus, MD, *Chair*, Brussels, Belgium; Artur Klett, MD, FEBO, *Liaison*, Tallinn, Estonia; Maria Borrelli, MD, PhD, Düsseldorf, Germany; Gerd Geerling, MD, PhD, FEBO, Düsseldorf, Germany

Financial Disclosures

Academy staff members who contributed to the development of this product state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

The authors and reviewers state that within the past 12 months, they have had the following financial relationships:^{*}

Dr Browning: Aerpio (S), Alimera Sciences (C), Diabetic Retinopathy Clinical Research (S), Genentech (S), Novartis Pharmaceuticals (S), Pfizer (S), Regeneron Pharmaceuticals (S)

Dr Durairaj: KLS Martin (L), Stryker Corporation/Medical Division (L)

Dr Fante: Ophthalmic Mutual Insurance Company (C, L)

Dr Foster: Allergan (C, L), Merz (C, L)

Dr Fouraker: Addition Technology (C), Alcon Laboratories (C), Keravision (C), Ophthalmic Mutual Insurance Company (C)

Dr Geerling: Allergan (C, L), Bausch + Lomb (C, L), TearLab (C, L, O), TearScience (C, L), Théa Pharma (C, L)

Dr Grosser: Ivantis (O)

Dr Isbey: Alcon Laboratories (S), Allscripts (C), Bausch + Lomb (S), Medflow (C)

Dr Korn: Elsevier (P)

Dr Raus: Allergan (L)

Dr Savage: Allergan (L)

The other authors and reviewers state that within the past 12 months, they have had no financial interest in or other relationship with any entity discussed in this course that produces, markets, resells, or distributes ophthalmic health care goods or services consumed by or used in patients, or with any competing commercial product or service.

*C = consultant fees, paid advisory boards, or fees for attending a meeting; L = lecture fees (honoraria), travel fees, or reimbursements when speaking at the invitation of a commercial sponsor; O = equity ownership/stock options of publicly or privately traded firms (excluding mutual funds) with manufacturers of commercial ophthalmic products or commercial ophthalmic services; P = patents and/or royalties that might be viewed as creating a potential conflict of interest; S = grant support for the past year (all sources) and all sources used for a specific talk or manuscript with no time limitation

Recent Past Faculty

Warren J. Chang, MD

Roberta E. Gausas, MD

Andrew R. Harrison, MD

John Bryan Holds, MD

In addition, the Academy gratefully acknowledges the contributions of numerous past faculty and advisory committee members who have played an important role in the development of previous editions of the Basic and Clinical Science Course.

American Academy of Ophthalmology Staff

Dale E. Fajardo, *Vice President, Education*

Beth Wilson, *Director, Continuing Professional Development*

Ann McGuire, *Acquisitions and Development Manager*

Stephanie Tanaka, *Publications Manager*

D. Jean Ray, *Production Manager*

Kimberly Torgerson, *Publications Editor*

Beth Collins, *Medical Editor*

Naomi Ruiz, *Editorial Assistant*

American Academy of Ophthalmology
655 Beach Street
Box 7424
San Francisco, CA 94120-7424

Contents

| | |
|--|-----------|
| General Introduction | xv |
| Objectives | 1 |
| PART I Orbit | 3 |
| 1 Orbital Anatomy | 5 |
| Dimensions | 5 |
| Topographic Relationships | 5 |
| Roof of the Orbit | 6 |
| Lateral Wall of the Orbit | 7 |
| Medial Wall of the Orbit | 8 |
| Floor of the Orbit | 8 |
| Apertures | 9 |
| Ethmoidal Foramina | 9 |
| Superior Orbital Fissure | 9 |
| Inferior Orbital Fissure | 9 |
| Zygomaticofacial and Zygomaticotemporal Canals | 9 |
| Nasolacrimal Canal | 10 |
| Optic Canal | 10 |
| Soft Tissues | 11 |
| Periorbita | 11 |
| Intraorbital Optic Nerve | 11 |
| Extraocular Muscles and Orbital Fat | 11 |
| Annulus of Zinn | 12 |
| Vasculation of the Orbit | 13 |
| Nerves | 16 |
| Lacrimal Gland | 18 |
| Periorbital Structures | 18 |
| Nose and Paranasal Sinuses | 18 |
| 2 Evaluation of Orbital Disorders | 21 |
| History | 21 |
| Pain | 21 |
| Progression | 21 |
| Periorbital Changes | 22 |
| Physical Examination | 23 |
| Inspection | 23 |
| Palpation | 25 |
| Auscultation | 26 |

| | |
|--|-----------|
| Primary Studies | 26 |
| Computed Tomography | 26 |
| Magnetic Resonance Imaging | 28 |
| Comparison of CT and MRI | 29 |
| Ultrasonography | 31 |
| Secondary Studies | 32 |
| Venography | 32 |
| Arteriography | 32 |
| CT and MR Angiography | 32 |
| Pathology | 32 |
| Laboratory Studies | 33 |
| 3 Congenital Orbital Anomalies | 35 |
| Anophthalmia | 35 |
| Microphthalmia | 35 |
| Treatment of Anophthalmia/Microphthalmia | 36 |
| Craniofacial Clefting and Syndromic Congenital | |
| Craniofacial Anomalies | 36 |
| Congenital Orbital Tumors | 39 |
| Hamartomas and Choristomas | 39 |
| 4 Orbital Inflammatory and Infectious Disorders | 43 |
| Infectious Inflammation | 44 |
| Cellulitis | 44 |
| Necrotizing Fascitis | 48 |
| Orbital Tuberculosis | 49 |
| Zygomycosis | 50 |
| Aspergillosis | 50 |
| Parasitic Diseases | 51 |
| Noninfectious Inflammation | 51 |
| Thyroid Eye Disease | 51 |
| IgG4 Disease | 60 |
| Vasculitis | 60 |
| Sarcoidosis | 63 |
| Nonspecific Orbital Inflammation | 63 |
| 5 Orbital Neoplasms and Malformations | 67 |
| Vascular Tumors, Malformations, and Fistulas | 67 |
| Infantile (Capillary) Hemangioma | 67 |
| Cavernous Hemangioma | 68 |
| Hemangiopericytoma | 69 |
| Lymphatic Malformation | 69 |
| Venous Malformation | 71 |
| Arteriovenous Malformation | 72 |
| Arteriovenous Fistula | 72 |
| Orbital Hemorrhage | 74 |

| | |
|--|------------|
| Neural Tumors | 74 |
| Optic Nerve Glioma | 74 |
| Neurofibroma | 77 |
| Meningioma | 78 |
| Schwannoma | 82 |
| Mesenchymal Tumors | 82 |
| Rhabdomyosarcoma | 82 |
| Miscellaneous Mesenchymal Tumors | 84 |
| Lymphoproliferative Disorders | 85 |
| Lymphoid Hyperplasia and Lymphoma | 85 |
| Plasma Cell Tumors | 89 |
| Histiocytic Disorders | 90 |
| Xanthogranuloma | 90 |
| Lacrimal Gland Tumors | 91 |
| Epithelial Tumors of the Lacrimal Gland | 91 |
| Nonepithelial Tumors of the Lacrimal Gland | 94 |
| Secondary Orbital Conditions | 94 |
| Globe and Eyelid Origin | 94 |
| Sinus Disease Affecting the Orbit | 95 |
| Metastatic Tumors | 98 |
| Metastatic Tumors in Children | 98 |
| Metastatic Tumors in Adults | 99 |
| Management of Orbital Metastases | 101 |
| 6 Orbital Trauma | 103 |
| Midfacial (Le Fort) Fractures | 103 |
| Orbital Fractures | 103 |
| Zygomatic Fractures | 103 |
| Orbital Apex Fractures | 106 |
| Orbital Roof Fractures | 106 |
| Medial Orbital Fractures | 106 |
| Orbital Floor Fractures | 108 |
| Intraorbital Foreign Bodies | 112 |
| Orbital Hemorrhage | 112 |
| Traumatic Vision Loss With Clear Media | 112 |
| 7 Orbital Surgery | 115 |
| Surgical Spaces | 115 |
| Orbitotomy | 116 |
| Superior Approach | 116 |
| Inferior Approach | 118 |
| Medial Approach | 118 |
| Lateral Approach | 120 |
| Orbital Decompression | 121 |
| Postoperative Care for Orbital Surgery | 124 |
| Special Surgical Techniques in the Orbit | 124 |
| Complications of Orbital Surgery | 124 |

| | |
|--|------------|
| 8 The Anophthalmic Socket | 127 |
| Enucleation and Evisceration | 128 |
| Enucleation | 128 |
| Evisceration | 129 |
| Intraoperative Complications of Enucleation and Evisceration | 130 |
| Orbital Implants | 131 |
| Prostheses | 132 |
| Anophthalmic Socket Complications and Treatment | 132 |
| Deep Superior Sulcus | 132 |
| Contracture of Fornices | 133 |
| Exposure and Extrusion of the Implant | 133 |
| Contracted Sockets | 134 |
| Anophthalmic Ectropion | 135 |
| Anophthalmic Ptosis | 135 |
| Lash Margin Entropion | 136 |
| Cosmetic Optics | 136 |
| Exenteration | 136 |
| Considerations for Exenteration | 136 |
| Types of Exenteration | 137 |
| PART II Periocular Soft Tissues | 139 |
| 9 Facial and Eyelid Anatomy | 141 |
| Face | 141 |
| Eyelids | 145 |
| Skin and Subcutaneous Tissue | 146 |
| Protractors | 147 |
| Orbital Septum | 149 |
| Orbital Fat | 149 |
| Retractors | 149 |
| Tarsus | 151 |
| Conjunctiva | 152 |
| Additional Anatomical Considerations | 152 |
| 10 Classification and Management of Eyelid Disorders | 155 |
| Congenital Anomalies | 155 |
| Blepharophimosis–Ptosis–Epicanthus Inversus Syndrome | 155 |
| Congenital Ptosis of the Upper Eyelid | 156 |
| Congenital Ectropion | 156 |
| Euryblepharon | 156 |
| Ankyloblepharon | 158 |
| Epicanthus | 158 |
| Epiblepharon | 159 |
| Congenital Entropion | 159 |
| Congenital Distichiasis | 160 |
| Congenital Coloboma | 160 |

| | |
|---|------------|
| Cryptophthalmos | 161 |
| Congenital Eyelid Lesions: Infantile (Capillary) Hemangioma | 161 |
| Acquired Eyelid Disorders | 162 |
| Chalazion | 162 |
| Hordeolum | 163 |
| Eyelid Edema | 164 |
| Floppy Eyelid Syndrome | 164 |
| Trichotillomania | 165 |
| Eyelid Neoplasms | 165 |
| Clinical Evaluation of Eyelid Tumors | 165 |
| Benign Eyelid Lesions | 166 |
| Benign Adnexal Lesions | 169 |
| Benign Melanocytic Lesions | 172 |
| Premalignant Epidermal Lesions: Actinic Keratosis | 175 |
| In Situ Epithelial Malignancies | 176 |
| Premalignant Melanocytic Lesions: Lentigo Maligna | 177 |
| Malignant Eyelid Tumors | 177 |
| Eyelid Trauma | 187 |
| Blunt Trauma | 187 |
| Penetrating Trauma | 187 |
| Secondary Repair | 189 |
| Dog and Human Bites | 190 |
| Burns | 190 |
| Eyelid and Canthal Reconstruction | 191 |
| Eyelid Defects Not Involving the Eyelid Margin | 191 |
| Eyelid Defects Involving the Eyelid Margin | 192 |
| Lateral Canthal Defects | 195 |
| Medial Canthal Defects | 195 |
| 11 Periocular Malpositions and Involutional Changes | 197 |
| History and Examination | 197 |
| Ectropion | 197 |
| Involutional Ectropion | 199 |
| Paralytic Ectropion | 201 |
| Cicatricial Ectropion | 201 |
| Mechanical Ectropion | 201 |
| Entropion | 202 |
| Congenital Entropion | 202 |
| Involutional Entropion | 202 |
| Acute Spastic Entropion | 205 |
| Cicatricial Entropion | 206 |
| Symblepharon | 208 |
| Trichiasis | 208 |
| Management | 208 |
| Blepharoptosis | 209 |
| Evaluation | 209 |

| | |
|---|------------|
| Physical Examination | 209 |
| Ancillary Tests | 212 |
| Classification | 213 |
| Treatment of Ptosis | 218 |
| Eyelid Retraction | 222 |
| Treatment of Eyelid Retraction | 223 |
| Facial Paralysis | 224 |
| Paralytic Ectropion | 224 |
| Upper Eyelid Paralysis | 226 |
| Facial Dystonia | 226 |
| Benign Essential Blepharospasm | 226 |
| Hemifacial Spasm | 228 |
| Involutorial Periorbital Changes | 229 |
| Dermatochalasis | 229 |
| Blepharochalasis | 230 |
| Blepharoplasty | 230 |
| Upper Eyelid | 230 |
| Lower Eyelid | 230 |
| Preoperative Evaluation for Blepharoplasty | 231 |
| Techniques | 232 |
| Complications | 233 |
| Brow Ptosis | 234 |
| Treatment of Functional Brow Ptosis | 234 |
| Facial Rejuvenation | 235 |
| Pathogenesis of the Aging Face | 236 |
| Physical Examination of the Aging Face | 236 |
| Nonsurgical Facial Rejuvenation | 237 |
| Laser Skin Resurfacing | 237 |
| Cosmetic Uses of Botulinum Toxin | 238 |
| Soft Tissue Dermal Fillers | 239 |
| Facial Rejuvenation Surgery | 241 |
| Forehead Rejuvenation | 241 |
| Midface Rejuvenation | 241 |
| Lower Face and Neck Rejuvenation | 245 |
| Conclusion | 247 |
| PART III Lacrimal System | 249 |
| 12 Anatomy, Development, and Physiology of the Lacrimal Secretory and Drainage Systems | 251 |
| Normal Anatomy | 251 |
| Secretory System | 251 |
| Drainage System | 252 |
| Development | 255 |
| Secretory System | 255 |
| Drainage System | 255 |
| Physiology | 255 |

13 Abnormalities of the Lacrimal Secretory and Drainage Systems

| | |
|---|-----|
| and Drainage Systems | 257 |
| Developmental Abnormalities | 257 |
| Lacrimal Secretory System | 257 |
| Lacrimal Drainage System | 257 |
| Congenital Lacrimal Drainage Obstruction | 259 |
| Evaluation | 259 |
| Punctal and Canalicular Agenesis and Dysgenesis | 259 |
| Congenital Nasolacrimal Duct Obstruction | 260 |
| Dacryocystocele | 265 |
| Acquired Lacrimal Drainage Obstruction | 267 |
| Evaluation | 267 |
| Punctal Disorders | 272 |
| Canalicular Obstruction | 273 |
| Acquired Nasolacrimal Duct Obstruction | 276 |
| Therapeutic Closure of the Lacrimal Drainage System | 281 |
| Trauma | 282 |
| Canaliculus | 282 |
| Lacrimal Sac and Nasolacrimal Duct | 284 |
| Infection | 284 |
| Dacryoadenitis | 284 |
| Canaliculitis | 284 |
| Dacryocystitis | 285 |
| Neoplasm | 286 |
| Lacrimal Gland | 286 |
| Lacrimal Drainage System | 287 |
| Basic Texts | 289 |
| Related Academy Materials | 291 |
| Requesting Continuing Medical Education Credit | 293 |
| Study Questions | 295 |
| Answer Sheet for Section 7 Study Questions | 301 |
| Answers | 303 |
| Index | 307 |

General Introduction

The Basic and Clinical Science Course (BCSC) is designed to meet the needs of residents and practitioners for a comprehensive yet concise curriculum of the field of ophthalmology. The BCSC has developed from its original brief outline format, which relied heavily on outside readings, to a more convenient and educationally useful self-contained text. The Academy updates and revises the course annually, with the goals of integrating the basic science and clinical practice of ophthalmology and of keeping ophthalmologists current with new developments in the various subspecialties.

The BCSC incorporates the effort and expertise of more than 90 ophthalmologists, organized into 13 Section faculties, working with Academy editorial staff. In addition, the course continues to benefit from many lasting contributions made by the faculties of previous editions. Members of the Academy Practicing Ophthalmologists Advisory Committee for Education, Committee on Aging, and Vision Rehabilitation Committee review every volume before major revisions. Members of the European Board of Ophthalmology, organized into Section faculties, also review each volume before major revisions, focusing primarily on differences between American and European ophthalmology practice.

Organization of the Course

The Basic and Clinical Science Course comprises 13 volumes, incorporating fundamental ophthalmic knowledge, subspecialty areas, and special topics:

- 1 Update on General Medicine
- 2 Fundamentals and Principles of Ophthalmology
- 3 Clinical Optics
- 4 Ophthalmic Pathology and Intraocular Tumors
- 5 Neuro-Ophthalmology
- 6 Pediatric Ophthalmology and Strabismus
- 7 Orbit, Eyelids, and Lacrimal System
- 8 External Disease and Cornea
- 9 Intraocular Inflammation and Uveitis
- 10 Glaucoma
- 11 Lens and Cataract
- 12 Retina and Vitreous
- 13 Refractive Surgery

In addition, a comprehensive Master Index allows the reader to easily locate subjects throughout the entire series.

References

Readers who wish to explore specific topics in greater detail may consult the references cited within each chapter and listed in the Basic Texts section at the back of the book.

These references are intended to be selective rather than exhaustive, chosen by the BCSC faculty as being important, current, and readily available to residents and practitioners.

Videos

This edition of Section 7, *Orbit, Eyelids, and Lacrimal System*, includes videos related to topics covered in the book. The videos were selected by members of the BCSC faculty and are available to readers of the print and electronic versions of Section 7. Mobile-device users can scan the QR code below (a QR-code reader must already be installed on the device) to access the video content.

Study Questions and CME Credit

Each volume of the BCSC is designed as an independent study activity for ophthalmology residents and practitioners. The learning objectives for this volume are given on page 1. The text, illustrations, and references provide the information necessary to achieve the objectives; the study questions allow readers to test their understanding of the material and their mastery of the objectives. Physicians who wish to claim CME credit for this educational activity may do so by following the instructions given at the end of the book.

Conclusion

The Basic and Clinical Science Course has expanded greatly over the years, with the addition of much new text, numerous illustrations, and video content. Recent editions have sought to place greater emphasis on clinical applicability while maintaining a solid foundation in basic science. As with any educational program, it reflects the experience of its authors. As its faculties change and medicine progresses, new viewpoints emerge on controversial subjects and techniques. Not all alternate approaches can be included in this series; as with any educational endeavor, the learner should seek additional sources, including Academy Preferred Practice Pattern Guidelines.

The BCSC faculty and staff continually strive to improve the educational usefulness of the course; you, the reader, can contribute to this ongoing process. If you have any suggestions or questions about the series, please do not hesitate to contact the faculty or the editors.

The authors, editors, and reviewers hope that your study of the BCSC will be of lasting value and that each Section will serve as a practical resource for quality patient care.

Objectives

Upon completion of BCSC Section 7, *Orbit, Eyelids, and Lacrimal System*, the reader should be able to

- describe the normal anatomy and function of orbital and periocular tissues
 - identify general and specific pathophysiologic processes (including congenital, infectious, inflammatory, traumatic, neoplastic, and involutional) that affect the structure and function of these tissues
 - select appropriate examination techniques and protocols for diagnosing disorders of the orbit, eyelids, and lacrimal system
 - select from among the various imaging and ancillary studies available those that are most useful for the particular patient
 - describe appropriate differential diagnoses for disorders of the orbital and periocular tissues
 - state the indications for enucleation, evisceration, and exenteration
 - describe functional and cosmetic indications in the surgical management of eyelid and periorbital conditions
 - state the principles of medical and surgical management of conditions affecting the orbit, eyelids, and lacrimal system
 - identify the major postoperative complications of orbital, eyelid, and lacrimal system surgery
-